Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics

被引：0
|
作者：
Nael Al Koudsi
Jill C. Mwenifumbo
Edward M. Sellers
Neal L. Benowitz
Gary E. Swan
Rachel F. Tyndale
机构：
[1] University of Toronto,Centre for Addiction & Mental Health, and Department of Pharmacology
[2] University of California,Division of Clinical Pharmacology and Experimental Therapeutics, Medical Service, San Francisco General Hospital Medical Center, and Departments of Medicine, Psychiatry and Biopharmaceutical Sciences
[3] SRI International,Center for Health Sciences
[4] University of Toronto,undefined
来源：
European Journal of Clinical Pharmacology | 2006年 / 62卷
关键词：
CYP2A6; Nicotine metabolism; Polymorphism; Pharmacogenetics; Smoking;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：481 / 484
页数：3
相关论文
共 50 条
  • [21] In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function
    di Iulio, Julia
    Fayet, Aurelie
    Arab-Alameddine, Mona
    Rotger, Margalida
    Lubomirov, Rubin
    Cavassini, Matthias
    Furrer, Hansjakob
    Guenthard, Huldrych F.
    Colombo, Sara
    Csajka, Chantal
    Eap, Chin B.
    Decosterd, Laurent A.
    Telenti, Amalio
    PHARMACOGENETICS AND GENOMICS, 2009, 19 (04) : 300 - 309
  • [22] Rational design of novel CYP2A6 inhibitors
    Tani, Niina
    Juvonen, Risto O.
    Raunio, Hannu
    Fashe, Muluneh
    Leppanen, Jukka
    Zhao, Bin
    Tyndale, Rachel F.
    Rahnasto-Rilla, Minna
    BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (23) : 6655 - 6664
  • [23] CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation
    Kubota, T
    Nakajima-Taniguchi, C
    Fukuda, T
    Funamoto, M
    Maeda, M
    Tange, E
    Ueki, R
    Kawashima, K
    Hara, H
    Fujio, Y
    Azuma, J
    PHARMACOGENOMICS JOURNAL, 2006, 6 (02) : 115 - 119
  • [24] A compensatory effect upon splicing results in normal function of the CYP2A6*14 allele
    Bloom, A. Joseph
    Harari, Oscar
    Martinez, Maribel
    Zhang, Xiaochun
    McDonald, Sandra A.
    Murphy, Sharon E.
    Goate, Alison
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (03) : 107 - 116
  • [25] High prevalence of CYP2A6*4 and CYP2A6*9 alleles detected among a Malaysian population
    Yusof, Wardah
    Gan, Siew Hua
    CLINICA CHIMICA ACTA, 2009, 403 (1-2) : 105 - 109
  • [26] CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation
    T Kubota
    C Nakajima-Taniguchi
    T Fukuda
    M Funamoto
    M Maeda
    E Tange
    R Ueki
    K Kawashima
    H Hara
    Y Fujio
    J Azuma
    The Pharmacogenomics Journal, 2006, 6 : 115 - 119
  • [27] Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy
    V Malaiyandi
    C Lerman
    N L Benowitz
    C Jepson
    F Patterson
    R F Tyndale
    Molecular Psychiatry, 2006, 11 : 400 - 409
  • [28] Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy
    Malaiyandi, V
    Lerman, C
    Benowitz, NL
    Jepson, C
    Patterson, F
    Tyndale, RF
    MOLECULAR PSYCHIATRY, 2006, 11 (04) : 400 - 409
  • [29] Nicotine metabolism:: the impact of CYP2A6 on estimates of additive genetic influence
    Swan, GE
    Benowitz, NL
    Lessov, CN
    Jacob, P
    Tyndale, RF
    Wilhelmsen, K
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (02) : 115 - 125
  • [30] Novel CYP2A6 diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism
    Tanner, Julie-Anne
    Zhu, Andy Z.
    Claw, Katrina G.
    Prasad, Bhagwat
    Korchina, Viktoriya
    Hu, Jianhong
    Doddapaneni, HarshaVardhan
    Muzny, Donna M.
    Schuetz, Erin G.
    Lerman, Caryn
    Thummel, Kenneth E.
    Scherer, Steven E.
    Tyndale, Rachel F.
    PHARMACOGENETICS AND GENOMICS, 2018, 28 (01) : 7 - 16
12345